Last reviewed 2026-04-19 · How we verify

Glasdegib Supra-therapeutic Exposure

Pfizer · Phase 1 active Small molecule

Glasdegib Supra-therapeutic Exposure is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.

At a glance

Generic name	Glasdegib Supra-therapeutic Exposure
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glasdegib Supra-therapeutic Exposure CI brief — competitive landscape report
Glasdegib Supra-therapeutic Exposure updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Glasdegib Supra-therapeutic Exposure

What is Glasdegib Supra-therapeutic Exposure?

Glasdegib Supra-therapeutic Exposure is a Small molecule drug developed by Pfizer.

Who makes Glasdegib Supra-therapeutic Exposure?

Glasdegib Supra-therapeutic Exposure is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is Glasdegib Supra-therapeutic Exposure in?

Glasdegib Supra-therapeutic Exposure is in Phase 1.

Manufacturer: Pfizer — full pipeline
Compare: Glasdegib Supra-therapeutic Exposure vs similar drugs
Pricing: Glasdegib Supra-therapeutic Exposure cost, discount & access